NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Shares Soar on Positive Phase 3 Trial of ZX008; Reaffirmed with ‘Buy’ Rating at Mizuho
Shares of Zogenix, Inc. (NASDAQ: ZGNX) clipped a new 52-week high earlier today after the company said its ZX008 for Dravet Syndrome (DS) met its primary endpoint in a phase 3 trial. ZX008 is designated as an orphan drug in both the U.S. and Europe, and it has received Fast Track designation in the U.S. for the treatment of DS. “On behalf of everyone at Zogenix, I would like to extend my sincere appreciation to the patients, families and investigators involved in this study. We are extremely pleased with the top-line efficacy and safety results from Study 1 which reinforce the…







